Albireo Pharma

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alberio Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2019 Results - Earnings Call Transcript

Shares have risen by over 50% since my initial recommendation in 2017.

Albireo Pharma: Updates To Thesis, Key Readouts In 2020

Albireo differentiates from adult cholestatic liver diseases by clinically focusing on the pediatric patient population, orphan diseases, and limiting enterohepatic recirculation.

Albireo And Odevixibat In Orphan Pediatric Cholestatic Liver Diseases: Making Magnificent Progress

Liver Therapy Forum digest provides an overview of what's happening in the NASH landscape in 2019. This week focuses on Albireo Pharma.

Albireo And Elobixibat In NASH, And The Market Assessment

Albireo Pharma, Inc. (ALBO) CEO Ronald Cooper on Q1 2019 Results - Earnings Call Transcript

News for Albireo Pharma Stock (ALBO)